Loading... Please wait...

Our Newsletter

NVP-AUY922 | HSP90 inhibitor

  • NVP-AUY922.jpg
  • NVP-AUY922, 400x400px, png
Catalog #:

Product Description

NVP-AUY922 is a resorcinol-based, intravenous or intraperitoneal Phase II clinical trial HSP90 inhibitor with a Kd of 1.7 nM. It inhibits tumor cell proliferation at GI50 values of 2-40 nM, inducing G1-G2 arrest and apoptosis. [1] Daily dosing of NVP-AUY922 (50 mg/kg, iv or ip) produced statistically significant tumor inhibition or regression (treated/control) in BT474 breast, 21%; A2780 ovarian, 11%; U87MG glioblastoma, 7%; PC3 prostate, 37%; and WM266.4 melanoma, 31%. [1]

Pharmacodynamically, NVP-AUY922 induces HSP70 and depletes ERBB2, CRAF, CDK4, phospho-AKT/TotalAKT, and HIF-1a.

Technical information:

Chemical Formula:   C26H31N3O5
CAS #:   747412-49-3
Molecular Weight:   465.54
Purity:   >99%
Appearance:   White
Chemical Name:   5-(2,4-dihydroxy-5-isopropylphenyl)-N-ethyl-4-(4-(morpholinomethyl)phenyl)isoxazole-3-carboxamide
Solubility:   Up to 100 mM in DMSO
Synonyms:   NVP-AUY-922; AUY922; VER-52296. Ver52296

Shipping Condition: The product is shipped in a glass vial at ambient temperature.
Storage condition: For longer shelf life, store solid powder at 4oC desiccated, or store DMSO solution at -20oC.


1. Eccles et al., NVP-AUY922: a novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasis. Cancer Res. 2008, 68, 2850-2860. Pubmed ID: 18413753

Other Information:

Product Specification (pdf)
MSDS (pdf)
Certificate of Analysis is available upon request.

Find Similar Products by Category

Write your own product review

Product Reviews

This product hasn't received any reviews yet. Be the first to review this product!

Add to Wish List

Click the button below to add the NVP-AUY922 | HSP90 inhibitor to your wish list.

You Recently Viewed...